开窗分支腔内主动脉修复术后二次干预对死亡率的影响
单中心回顾2010至2016年308例开窗分支腔内主动脉修复(F/BEVAR),24%患者接受二次干预(SI),多数为腔内修复,开放SI更常急诊。有无SI的1年生存88% vs 81%、5年76% vs 59%(P=.06),SI未显著影响院外生存。
要点
- F/BEVAR后24%患者需二次干预,多数为分支或主动脉装置腔内修复。
- 开放二次干预更常为急诊(89%,P=.001),需重点预防。
- 有无二次干预的5年生存76% vs 59%(P=.06),无显著差异。
核心结论
- F/BEVAR后二次干预常见但不负面影响的院外生存。
- 影像监测对维持F/BEVAR耐久性至关重要。
研究设计与样本
- 单中心回顾性分析2010至2016年连续308例F/BEVAR,平均随访20±21个月。
- 75%为医生改良、18%定制、7% Zfen;共重建1022支血管。
主要发现
- 24%(74例)发生二次干预:轻微腔内53%、重大腔内32%、开放12%、杂交3%。
- 二次干预主要适应症:分支相关内漏29%、主动脉退变22%、分支血栓/狭窄12%。
- 1年和3年免于二次干预率分别为80±3%和64±4%。
- 有无二次干预的1年生存88±4% vs 81±3%,5年76±5% vs 59±4%(P=.06)。
- 开放二次干预更常急诊(89%,P=.001);I-III型TAAA(HR 1.6,95%CI 0.98-3.3,P=.06)和脑血管病史(HR 1.8,95%CI 0.97-2.6,P=.07)预测二次干预。
临床怎么用
- F/BEVAR术后应加强影像监测以早期发现并处理装置相关二次干预事件。
- 对开放二次干预高风险患者应优化围术期规划与器械设计。
局限性
- 单中心回顾性设计,样本量有限且随访时间较短。
- 二次干预对生存的影响未达统计学显著性,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fenestrated and branched endovascular aortic repair (F/BEVAR) is increasingly used to manage pararenal and thoracoabdominal aortic disease (TAAA). Device-related reintervention after F/BEVAR is common, but little is known about its impact on postoperative mortality. The purpose of this analysis was to describe secondary intervention (SI) after F/BEVAR and determine the impact of these procedures on patient survival. METHODS: A single-center review was done on all consecutive F/BEVARs performed from 2010 to 2016. Primary end points were incidence of secondary aortic, branch, and/or access vessel‒related SI, and survival. SI was categorized as minor endovascular (branch restenting, access vessel treatment, or percutaneous coil embolization), major endovascular (new aortic graft placement), or open (bleeding, access vessel, and/or aortic). Kaplan-Meier methodology was used to estimate freedom from SI and survival. Multivariable analysis was used to identify predictors of SI. RESULTS: A total of 308 F/BEVAR procedures were performed (75% physician-modified, 18% custom, 7% Zfen), with 1022 vessels revascularized (celiac, 228; superior mesenteric artery [SMA], 263; renal, 525). There were 117 (39%) extent I-III TAAA, 132 (44%) extent IV TAAA/4-vessel pararenal, and 54 (18%) <4-vessel pararenal repairs performed. Any type of SI occurred in 24% (74) of patients during the mean follow-up of 20 ± 21 months. The majority of reinterventions were endovascular (minor, 53% [n = 39]; major, 32% [n = 24]), whereas 12% (n = 9) were open and 3% (n = 2) hybrid. Primary indication for SI included: 22 (29%) with branch-related endoleaks (1C or III); 15 (22%) with proximal or distal aortic degeneration; 8 (12%) with branch vessel thrombosis/stenosis; 10 (11%) with aortic device type III endoleak/loss of overlap; 4 (6%) with postoperative mesenteric or renal bleeding events; 5 (5%) with type II endoleak; 3 (5%) with access vessel complication; and 2 (3%) with graft infection. Most SIs were elective (65%; n = 48) with the remainder occurring emergently (24%; n = 18) or for symptoms/urgently (11%; n = 8). Compared with endovascular remediation, open SI was more likely to be emergent (89%, 8 of 9; P = .001). Freedom from SI was 80 ± 3% and 64 ± 4% at 1 and 3 years, respectively. One- and 5-year survival with or without SI was: 1 year, 88 ± 4% vs 81 ± 3%; 5 years, 76 ± 5% vs 59 ± 4% (log rank test, P = .06). There was no survival difference based on type of SI (log rank test, P = .3). Extent I-III TAAA (HR, 1.6; 95% CI, 0.98-3.3; P = .06) and history of cerebrovascular disease (HR, 1.8; 95% CI, 0.97-2.6; P = .07) were predictive of SI. CONCLUSIONS: SIs after F/BEVAR most frequently involve branch vessel or aortic device remediation procedures; however, they do not negatively impact out-of-hospital survival. These results further highlight the crucial role of imaging surveillance after F/BEVAR to maintain durability. Discussions with patients, periprocedural planning, and the next generation of device design must focus on issues surrounding the risk of device-related SI events.
引用
- Giles KA, Scali ST, Pearce BJ, et al. Impact of secondary interventions on mortality after fenestrated branched endovascular aortic aneurysm repair. J Vasc Surg. 2019. PMID: 31420254. doi:10.1016/j.jvs.2019.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。